YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
Jaká je dnes cena akcie společnosti YiChang HEC ChangJiang Pharmaceutical?▼
Aktuální cena akcie 1558.HK je HK$15,88 HKD — za posledních 24 hodin klesla o -0,5%. Vývoj ceny akcie společnosti YiChang HEC ChangJiang Pharmaceutical můžete podrobněji sledovat v grafu.
Jaký ticker má akcie společnosti YiChang HEC ChangJiang Pharmaceutical?▼
Ticker akcie se může lišit podle burzy. Například na burze Hong Kong Exchange se akcie společnosti YiChang HEC ChangJiang Pharmaceutical obchodují pod tickerem 1558.HK.
Jaké byly tržby společnosti YiChang HEC ChangJiang Pharmaceutical za minulý rok?▼
Tržby společnosti YiChang HEC ChangJiang Pharmaceutical za poslední rok činí 3,99B HKD.
Jaký je čistý zisk společnosti YiChang HEC ChangJiang Pharmaceutical za minulý rok?▼
Čistý zisk 1558.HK za poslední rok činí 520,74M HKD.